摘要
目的:研究射麻止喘方联合孟鲁斯特钠治疗支气管哮喘的疗效。方法:将118例患者按随机数字表法分为对照组59例和观察组59例。对照组给予孟鲁斯特钠治疗,观察组给予射麻止喘方联合孟鲁斯特钠治疗。进行治疗前后哮喘控制调查问卷(ACT)评分、支气管哮喘生活质量问卷(AQLQ)评分;检测治疗前后肺功能指标、白细胞介素-4(IL-4)、白细胞介素-10(IL-10)、白细胞介素-18(IL-18)、白细胞介素-25(IL-25)水平;并统计两组临床治疗总有效率。结果:治疗后观察组总有效率优于对照组(χ2=4.196,P<0.05);与治疗前相比较,两组喘息、咳嗽、咳痰、胸闷及哮鸣音积分较治疗前下降(均P<0.05),治疗后组间比较发现,观察组中医症状、体征积分低于对照组(均P<0.05);与治疗前相比较,两组第1秒用力呼气容积(FEV1)、呼气流量峰值(PEF)水平较治疗前上升(均P<0.05),治疗后组间比较发现,观察组FEV1、PEF水平高于对照组(均P<0.05);与治疗前相比较,两组IL-4、IL-10、IL-18、IL-25水平较治疗前下降(均P<0.05),治疗后组间比较发现,观察组IL-4、IL-10、IL-18、IL-25水平低于对照组(均P<0.05);与治疗前相比较,两组ACT评分、AQLQ评分较治疗前上升(均P<0.05),治疗后组间比较发现,观察组ACT评分、AQLQ评分高于对照组(均P<0.05)。结论:在孟鲁斯特钠治疗基础上,内服射麻止喘方治疗支气管哮喘可减轻炎症反应,缓解临床症状,提高生活质量和临床疗效。
Objective:To study the therapeutic effect of Shema Zhichuan recipe combined with montelukast sodium in treating bronchial asthma.Methods:118 patients were randomly divided into 59 in the control group and 59 in the observation group according to the digital table method.The control group was treated with montelukast sodium,and the observation group with Shema Zhichuan prescription combined with montelukast sodium.The asthma control questionnaire(ACT)score,bronchial asthma quality of life questionnaire(AQLQ)score before and after treatment;the pulmonary function index,interleukin-4(IL-4),interleukin-10(IL-10),interleukin-18(IL-18),interleukin-25(IL-25)levels were measured before and after treatment;and the total effective rate of clinical treatment in the two groups were counted.Results:The total effective rate of the observation group after treatment was better than that of the control group(χ2=4.196,P<0.05).The scores of wheezing,cough,expectoration,chest tightness and wheezing in the two groups were lower than those before treatment(all P<0.05).After treatment,the scores of TCM symptoms and signs in the observation group were lower than those in the control group(all P<0.05).Compared with before treatment,the levels of forced expiratory volume(FEV 1)and peak expiratory flow(PEF)in the first second of the two groups were higher than those in the control group(all P<0.05).After treatment,the FEV 1、PEF level in the observation group was higher than that in the control group(P<0.5);compared with pre-treatment,IL-4、IL-10、IL-18、IL-25 level in the observation group was lower than that of the control group(all P<0.05),and the ACT score and AQLQ score of the two groups were higher than that in the control group(all P<0.05).Conclusion:On the basis of montelukast sodium treatment,internal administration of zaima zhichuan prescription for bronchial asthma can alleviate the inflammatory response,relieve clinical symptoms,improve the quality of life and clinical efficacy.
作者
邱世光
王高岸
李雅琴
方翔宇
QIU Shiguang;WANG Gao’an;LI Yaqin;FANG Xiangyu(The Second Affiliated Hospital of Hainan Medical University,Haikou 570311,China)
出处
《陕西中医》
2021年第2期172-176,共5页
Shaanxi Journal of Traditional Chinese Medicine
基金
海南省重点研发计划科技合作方向项目(ZDYF2019210)。
关键词
射麻止喘方
孟鲁斯特钠
支气管哮喘
炎症反应
生活质量
肺功能
Shema Zhichuan recipe
Monroust sodium
Bronchial asthma
Inflammatory response
Quality of life
Pulmonary function